Public Employees Retirement System of Ohio Increases Stock Position in Ascendis Pharma A/S $ASND

Public Employees Retirement System of Ohio lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 245.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,977 shares of the biotechnology company’s stock after purchasing an additional 14,193 shares during the period. Public Employees Retirement System of Ohio’s holdings in Ascendis Pharma A/S were worth $5,328,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ASND. Cetera Investment Advisers purchased a new stake in Ascendis Pharma A/S in the 2nd quarter valued at about $552,000. Rhumbline Advisers boosted its stake in shares of Ascendis Pharma A/S by 4.0% in the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after buying an additional 55 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Ascendis Pharma A/S by 66.2% in the second quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 1,488 shares in the last quarter. Qube Research & Technologies Ltd grew its holdings in shares of Ascendis Pharma A/S by 83.4% in the second quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after acquiring an additional 91,412 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Ascendis Pharma A/S during the second quarter valued at approximately $897,000.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of recent analyst reports. UBS Group set a $345.00 price target on Ascendis Pharma A/S in a report on Monday. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. TD Cowen raised their target price on Ascendis Pharma A/S from $325.00 to $341.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Oppenheimer lifted their target price on Ascendis Pharma A/S from $304.00 to $312.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, Jefferies Financial Group cut their price target on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating on the stock in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $310.05.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $267.31 on Thursday. The stock has a fifty day simple moving average of $257.46 and a two-hundred day simple moving average of $240.09. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15. The firm has a market cap of $16.67 billion, a price-to-earnings ratio of 20.74 and a beta of 0.35. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Analysts anticipate that Ascendis Pharma A/S will post 6.08 earnings per share for the current year.

Key Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Oppenheimer raised its price target to $312 from $304 while maintaining an “Outperform” rating, indicating increased confidence in Ascendis Pharma’s outlook. Oppenheimer Adjusts Price Target on Ascendis Pharma
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $345 price target while dramatically increasing its FY2026 earnings-per-share forecast to $17.04 from $3.93. The upgrade provides a significant bullish earnings catalyst, although it contrasts with the firm’s lower estimates for later periods.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating and set a $327 price target, suggesting substantial potential upside from the reference price. Wedbush Reaffirms Ascendis Pharma Outperform Rating
• Positive Sentiment: Ascendis Pharma received an average analyst rating of “Buy,” reinforcing broadly favorable Wall Street sentiment. Ascendis Pharma Receives Average Buy Rating
• Neutral Sentiment: HC Wainwright lowered its FY2027 EPS forecast to $11.25 from $11.88 and reduced estimates for several 2026–2027 quarters. However, the firm retained its Buy rating and $345 target, suggesting the revisions may reflect timing or modeling changes rather than a change in its overall investment thesis.
• Negative Sentiment: Bank of America lowered its price target to $304, creating a modest counterpoint to the positive revisions from Oppenheimer, Wedbush and HC Wainwright. Bank of America Lowers Ascendis Pharma Price Target

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 2,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the acquisition, the director directly owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.